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The concept of adoptive cell therapy (ACT) was born 
more than 70 years ago with the purpose to ready 
supply immune-associated weapons for fighting lethal 
diseases, such as cancer. This strategy overcomes the 
limitations of cancer vaccines based on developing a 
tumor specific immune response in immune 
compromised tumor bearing hosts in which a tolerance 
against tumor antigens has been already established. 
The first clinical trial exploiting T cell-based ACT was 
performed in 1988 on melanoma patients: tumor 
infiltrating T lymphocytes (TILs) were isolated from 
melanoma tumors and infused in the same patients after 
ex vivo expansion. Since that, many advances were 
reached. Today the most challenging issues limiting the 
efficacy of patient-derived tumor specific T cell 
adoptive transfer relied both on the terminal 
differentiation status of transferred T cells and on their 
low affinity binding to tumor associated antigens 
(TAA), which are proteins expressed in healthy tissues 
even if at a lower level. The elimination of most 
reactive clones targeting self-proteins is indeed the 
consequence of central tolerance action on T cell 
repertoire. DNA engineering techniques circumvented 
this issue. Transgenic T cell receptors (TCRs) or 
chimeric antigen receptors (CARs) conferred the ability 
of recognizing TAA with higher affinity and eventually 
without MHC restriction, unleashing thus all the 
cytotoxic arsenal of T cells against tumor. The higher 
chances to target self-tissues, which raise when central 
tolerance is by-passed, represents the most important 
concern. Thus the choice of the TAA and of the TCR 
avidity is crucial to reach the greatest efficacy on tumor 
with low risk of off-targets and consequent side effects. 
In this context, telomerase reverse transcriptase 
(TERT), a protein that extends chromosomal ends 
(telomeres) preventing genomic instability and allowing 
indefinite cell proliferation potential, represents an ideal 
candidate. Indeed, TERT is generally expressed at very 
low levels in healthy tissues characterized by high self-
renewal abilities (such as bone marrow and testes) 
whereas it is reactivated in cancer cells. In fact, TERT 
activity is observed in about 85% of human tumors of 
various histological types qualifying this protein as a 
universal tumor antigen (UTA) [1]. By using a DNA 
vaccine targeting mouse TERT, we recently isolated a 
polyclonal cytotoxic T lymphocytes (CTLs) population 
recognizing   mTERT198-205   in  H2-Kb  context  able  to  








restrict growth of different types of tumors after their in 
vivo infusion with very low side effects [2]. To prove 
the translating potential of our findings we mirrored the 
experiment set up in a human setting: after vaccinating 
HLA-A*0201 transgenic mice using human TERT 
encoding DNA, we identified in vitro several clones 
able to recognize a large number of cancer cell lines [2]. 
Moreover, we validated the ability of high affinity 
CTLs to in vivo control human cancer progression of 
both immortalized cancer cells and, also, patient-
derived  HLA-matched cancer stem cells [2]. Therefore, 
we decided to clone the sequences of the α and β chains 
of the anti-telomerase TCR into a retroviral vector able 
to transduce naïve T cells [3]. ACT of hTERT865–873 
specific TCR-engineered  human T  cells  (PCT/IB2016/ 
051510) was able to control the in vivo progression of 
different human malignancies: human chronic 
lymphocytic leukemia (B-CLL) human B-cell acute 
lymphoblastic leukaemia (B-ALL), acute myeloid 
leukaemia (AML) and different solid cancers [3, 4]. 
Finally, our side effects studies on human immune 
reconstituted (HIR) mice showed very limited toxicity 
against mature granulocytes but not toward human 
hematopoietic progenitors [3]. Thus, the flexibility of 
usage on both solid and liquid tumors of this magic 
bullet, together with minimal safety concerns, qualify 
hTERT865–873 specific TCR-engineered human T cell 
ACT as a new precision weapon for cancer immune 
therapy (Figure 1). Nonetheless the cutting edge 
preclinical results, there is still space to improve the 
efficacy of TERT-specific CTL based ACT. Tumor 
progression is coupled with the development of an 
immune suppressive microenvironment hostile to T cell 
homing and function: the induction of a more favorable 
milieu for T lymphocytes represents thus a critical 
requirement for enhancing T cell fitness and action on 
tumor cells. In this context, we recently designed and 
positively tested a drug able to block the in vivo 
generation of peroxynitrites and to improve consequent-
ly transferred-T cell infiltration and persistence at the 
tumor site [5]. We also dissected the role of 
complement system activation on tumor endothelium in 
orchestrating T cell homing to tumor after ACT [6]; as 
well as, we identified a specific subset of dendritic cells, 
named TipDC, characterized as inducible nitric oxide 
synthase (iNOS) and tumor necrosis factor α (TNFα) 
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when injected in the tumor-microenvironment [7]. In 
the next future, we plan to combine ACT with immune 
checkpoint inhibitors (anti-PD1, anti-PD-L1) to enhance 
T cells proliferation, survival and cytotoxic activity with 
the final aim of providing a long lasting immune 
therapy efficacy and protection against tumor recur-
rence. In conclusion, we believe that combination 
immunotherapy based on anti-telomerase T cells adop-
tive transfer together with immunomodulators will open 
a new frontier for cancer immunotherapy that will 
elevate the quality standards of patient care and will 
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Figure  1.  TERT‐based  adoptive  cell  therapy  is  an
universal  cancer  immunotherapeutic approach. hTERT865‐
873‐specific, TCR‐engineered T‐cells, as golden bullets, are able to
selectively  eliminate  antigen  positive  (yellow  spots)  specific
targets  such as  lymphoblastic and myeloid  leukaemia  cells and
different  solid  tumor  cells  without  affecting  normal  B  and  T
lymphocytes as well as stem cells.  
